The cyclin-dependent kinase 1 (Cdc2)/cyclin B1 complex performs cardinal roles for eukaryotic mitotic progression. Phosphorylation of four serine residues within cyclin B1 promotes the rapid nuclear translocation of Cdc2/cyclin B1 at the G 2 /M transition. Still, the role of individual phosphorylation sites and their corresponding kinases remain to be elucidated. Polo-like kinase 1 (Plk1) shows a spatial and temporal distribution which makes it a candidate kinase for the phosphorylation of cyclin B1. We could demonstrate the interaction of both proteins in mammalian cells. Plk1 phosphorylated wildtype cyclin B1 expressed in bacteria and in mammalian cells. Ser-133 within the cytoplasmic retention signal (CRS) of cyclin B1, which regulates the nuclear entry of the heterodimeric complex during prophase, is a target of Plk1. In contrast, MAPK (Erk2) and MPF phosphorylate Ser-126 and Ser-128 within the CRS. Phosphorylation of CRS by MAPK (Erk2) prior to Plk1 treatment induced enhanced phosphorylation of cyclin B1 by Plk 1 suggesting a synergistic action of both enzymes towards cyclin B1. In addition, pretreatment of cyclin B1 by MAPK (Erk2) altered the phosphorylation pattern of Plk 1. Mutation of Ser-133 to Ala decreased the phosphorylation of cyclin B1 in vivo. An immunofluorescence study revealed that a mutation of Ser-133 reduced the nuclear import rate of cyclin B1. Still, multiple serine mutations are required to prevent nuclear translocation completely indicating that orchestrated phosphorylation within the CRS triggers rapid import of cyclin B1.
Introduction
The onset of mitosis is regulated by the activation of MPF (maturation promoting factor) (Morgan, 1997; Ohi and Gould, 1999) . Phosphorylation of Cdc2 at two sites Thr-14 and Tyr-15 by the inhibitory kinases Wee1 and Myt1 prevents Cdc2 from premature activation before entry into mitosis (Solomon et al., 1992; Watanabe et al., 1995; Mueller et al., 1995) . Dephosphorylation of Cdc2 by the dual specificity phosphatase Cdc25 promotes Cdc2/cyclin B1 activation, which drives cells into mitosis Strausfeld et al., 1991) . Still, the mitotic function of Cdc2/cyclin B1 is triggered not only at the level of enzymatic activity but also by spatial control. In late prophase, most Cdc2/cyclin B1 heterodimers are imported into the nucleus (Clute and Hagting et al., 1999) . An aminoterminal region of cyclin B1 termed the cytoplasmic retention signal (CRS) accounts for the cytoplasmic localization of cyclin B1 during prophase. The steady-state localization of cyclin B1 is influenced in part by a nuclear export signal (NES) that binds to the nuclear transport factor CRM1 (exportin 1) mediating the export of cyclin B1 (Hagting et al., 1998 (Hagting et al., , 1999 . The balance of cyclin B1 localization in prophase is rapidly shifted to a predominant nuclear localization due to the inhibition of its export. Indeed, it was demonstrated that a phosphorylated CRS in cyclin B1 binds much less exportin 1 in Xenopus extracts (Yang et al., 1998) . In addition, import of human cyclin B1 with a mutated NES requires several hours (Hagting et al., 1998) . Thus, the cellular distribution of cyclin B1 is regulated by the relative rates of nuclear export and import.
Several lines of evidence indicate that the function of cyclin B1 is regulated through phosphorylation at multiple sites (Li et al., 1995; Yang et al., 1998 Yang et al., , 2000 Hagting et al., 1999) . At the time of Cdc2 dephosphorylation by Cdc25, cyclin B1 from various species (Yeast, Xenopus oocytes, human cells) becomes phosphorylated indicating the functional importance of this process (Booher et al., 1989; Gautier and Maller, 1991; Meijer et al., 1991) . In Xenopus Ser-2, Ser-94, Ser-96, Ser-101 and Ser-113 of cyclin B1 were shown to be phosphorylated (Li et al., 1995) . Autophosphorylation by the catalytic subunit of MPF seems to be a principal pathway for cyclin B1 phosphorylation at Ser-94 and Ser-96 in Xenopus (Borgne et al., 1999) . Furthermore, MAPK (mitogen-activated protein kinase) from Xenopus eggs phosphorylates cyclin B1 at Ser-94 or Ser-96 (Izumi and Maller, 1991) . Still, Ser-101 and Ser-113 in Xenopus corresponding to Ser-133 and Ser-147 in mammalian cells do not fit the consensus site for Cdc2-catalysed phosphorylation. Moreover, sequences flanking Ser-133 and Ser-147 are not homologues suggesting that other kinases might phosphorylate the CRS of cyclin B1.
Cyclin B1 expression varies throughout the cell cycle with its peak in G 2 /M. The temporal distribution of cyclin B1 during the cell cycle resembles the enzymatic kinetics of Plk1, a serine/threonine kinase which is conserved from yeasts to humans (Lake and Jelinek, 1993; Holtrich et al., 1994) . In addition to various studies that support a role of Plk1 for the commitment of cells to M phase, Plk1 seems to participate in the activation of the anaphase promoting complex and in late mitotic events such as cytokinesis (Nigg, 2001) . The leading role of cyclin B1 and Plk1 for the entry of mitosis prompted us to study their functional relationship in more detail.
Before we could close our study on Plk1 and cyclin B1, Toyoshima-Morimoto et al. (2001) revealed that the phosphorylation of Ser-147 within the NES of cyclin B1 by Plk1 regulates the translocation of cyclin B1 into the nucleus. Still, in our study Plk1 phosphorylated Ser-133 of cyclin B1 as partner kinase of MPF and MAPK (ERK2) regulating the phosphorylation and the nuclear shutteling of cyclin B1.
Results

Plk1 and cyclin B1 codistribute in mammalian cells
We studied the relative localization of cyclin B1 and Plk1 throughout the cell cycle by indirect immunofluorescence. While cyclin B1 localized mostly to the cytoplasm during S and G 2 phases, Plk1 was found in the cytoplasm as well as in the nucleus (Figure 1 ). In late prophase cyclin B1 and Plk1 accumulated in the nucleus (Figure 1 ). Cyclin B1 and Plk1 then bound to the mitotic spindle and chromosomes. Staining at spindle poles and chromosomes decreased during metaphase. While in telophase Plk1 accumulated at the midbody, immunofluorescence of cyclin B1 had disappeared due to degradation (Figure 1 ). Moreover, we used leptomycin B that binds CRM1, thereby preventing CRM1 dependent nuclear export of cyclin B1. While the treatment of HeLa S3 cells with leptomycin B (3 ng/ml) inhibited the export of cyclin B1 efficiently, the cellular distribution of Plk1 was not affected suggesting that Plk1 and cyclin B1 are not cotransported during mitosis (data not shown). Taken together, immunostaining demonstrated codistribution of endogenous Plk1 and cyclin B1 during late prophase. At metaphase both proteins colocalized at the mitotic apparatus mostly to the spindle poles.
Plk1 and cyclin B1 interact in vivo and in vitro
Since non-synchronized cells in culture contain only moderate levels of Plk1 and cyclin B1, recombinant vector-driven high frequency expression was helpful to analyse the putative interaction in more detail. We generated a chimera consisting of Plk1 and GFP to evaluate visually the efficiency of transfection. Only those COS-7 cultures, which exhibited a high level of fusion protein, were further analysed. Immunoprecipitates using antibodies directed against Plk1, cyclin B1 and Cdc2 were studied (Figure 2a ). Coprecipitation experiments with cyclin B1 antibodies demonstrated that a complex from mammalian cells contained cyclin B1, GFP (green fluorescent protein)-Plk1 and Cdc2 (Figure 2a , all panels, lanes 3). Prolonged exposure revealed also endogenous Plk1 as component of this complex (data not shown). The blot was then reprobed with monoclonal GFP-antibodies which confirmed that the coprecipitated protein at 100 kDa represents the GFP -Plk1 fusion protein (data not shown). In an analysis using confocal laserscanning microscopy cyclin B1 (green) was visualized using DTAF-conjugated antibodies and Plk1 (red) by Cy3-conjugated antibodies, respectively. Nuclei were stained with bisbenzimide (Hoechst 33342) to visualize chromatin condensation (data not shown) This interaction of Plk1 and cyclin B1 was also tested using endogenous protein from synchronized HeLa S3 cells or HeLa S3 cells transfected with cyclin B1 followed by synchronization. Their association could only be observed in mitosis (data not shown). Furthermore, only low amounts of coprecipitated protein were detectable which is likely due to the short half-life of the interaction.
To test further for a direct interaction between cyclin B1 and Plk1, 35 S-labeled cyclin B1 from rabbit reticulolysate was incubated with immunoprecipitated Plk1 bound to protein A-Sepharose beads. The examination revealed the interaction of Plk1 and cyclin B1 in vitro (Figure 2b , left panel, lane 3). Moreover, a GST-fusion protein of human Plk1 was bacterially expressed. The incubation of GST -Plk1 from E coli with in vitro-translated cyclin B1 demonstrated also the association of both proteins (Figure 2b , right panel, lane 4). Thus, the association of Plk1 and cyclin B1 does not seem to require accessory proteins or secondary modifications.
Plk1 phosphorylates full-length cyclin B1 expressed in bacteria or in human cells
After the examination of the subcellular localization and interaction of Plk1 and cyclin B1, we focused on functional aspects of this interaction. Since both, Plk1 and cyclin B1/Cdc2, exhibit serine/threonine kinase activity and are activated by phosphorylation, we tested whether these kinases have the potential for transphosphorylation. We could demonstrate that baculovirus-expressed Plk1 purified from Sf 9 cells phosphorylated full-length cyclin B1 expressed in bacteria ( Figure 3a) . Furthermore, we transfected 293 S-labeled cyclin B1. Material bound to protein A Sepharose was recovered and resolved by SDS -PAGE followed by autoradiography. Immunoprecipitated actin served as negative control. Right panel: GST or GST -Plk1 were purified from E. coli, bound to glutathione-Sepharose beads and incubated with 35 S-labeled cyclin B1 and luciferase as a control. Precipitates were analysed by SDS -PAGE followed by autoradiography. 10% of the starting lysate served as input control Figure 3 Plk1 phosphorylates full-length cyclin B1 expressed in bacteria or human cells. (a) Full-length cyclin B1 tagged with GST was expressed in E. coli and purified using GST-beads. One mg of GST and GST-cyclin B1 fusion proteins and 0.5 mg of casein were added in this kinase assay. Plk1 purified from Sf 9 cells phosphorylated cyclin B1 while GST alone did not serve as substrate. Casein served as a positive control for Plk1 kinase. (b) Plk1 phosphorylates cyclin B1 from human cells. CFP-cyclin B1 was purified by immunoprecipitation from 293 cells. Normal mouse IgG was used as negative control. The immunoprecipitate was split serving as substrate for kinase assays (upper panel) and for Western blot using cyclin B1 antibodies as an input control (lower panel) cells with cyclin B1 fused to cyan fluorescent protein (CFP). Immunoprecipitated cyclin B1 from these human cells served well as a substrate for Plk1 as shown in Figure 3b (upper panel). Taken together, Plk1 phosphorylated full-length cyclin B1 expressed in bacteria as well as in human cells.
The cytoplasmic retention signal (CRS) of cyclin B1 is a substrate for both mammalian-and baculovirus-expressed Plk1
Next we wondered which region of cyclin B1 might be a target for Plk1 kinase activity. When Plk1 exhibits its peak of enzymatic activity at the onset of mitosis, human cyclin B1 is phosphorylated on several conserved serines within the CRS, which are involved in regulating its biological activity (Li et al., 1997; Hagting et al., 1999) . Based on these observations we have focused our attention on the molecular basis of CRS phosphorylation considering Plk1 as candidate kinase. Since Plk1 activity reaches its peak at G 2 /M (Lee et al., 1995) , we examined whether Plk1 from HeLa S3 cells at G 2 /M has the ability to phosphorylate a bacterially expressed CRS-polypeptide (amino acids 100 -159 of human cyclin B1). Interestingly, weak phosphorylation of the CRS was visible (Figure 4a , lane 3). Phosphorylation of casein by immunoprecipitated Plk1 was also demonstrated ( Figure 4a , lane 4). Since we could not rule out that phosphorylation of CRS is due to kinases other than Plk1 coprecipitated from mammalian cells, we used purified human Plk1 from insect cells (Lin et al., 2000) . The kinase activity of Plk1 from baculovirus-infected cells towards GST-CRS was comparable to casein suggesting that the CRS of cyclin B1 is a good substrate for Plk1 (Figure 4b, lanes 2 and 3) .
Phosphorylation within a sequence connecting protein kinase subdomains VII and VIII was suggested as regulatory mechanism to many protein kinases. In line with this model it was demonstrated previously that mutation of Thr-210 to Asp (T210D) raised the in vitro activity of Plk1 expressed in Sf 9 cells towards casein fourfold (Lee et al., 1995; Lin et al., 2000) . Using this activated form of Plk1 (T210D) the phosphorylation towards CRS was clearly enhanced compared to wild-type Plk1 (Figure 4c, lanes 3 and 6) . In contrast, the inactive form of Plk1 (K82M) due to a mutation of Lys-82 to Met in the ATP-binding motif prevented phosphorylation of the CRS sequence completely (Figure 4c, lane 9) . In addition, we could demonstrate that Plk1 from Sf 9 cells phosphorylates the CRS in a dose-dependent manner (Figure 4d ). Thus, human Plk1 specifically phosphorylates the CRS of cyclin B1.
Ser-126 and Ser-128 within the CRS of cyclin B1 are phosphorylated by MPF and MAPK whereas Ser-133 is a phosphorylation site for human Plk1
Autophosphorylation of cyclin B1 by Cdc2 itself has been proposed in sea urchin eggs and in Xenopus oocytes (Gautier et al., 1990) . In addition, MAPK (Erk2) was also shown to phosphorylate Xenopus cyclin B1 (Izumi and Maller, 1991) . To ensure that GST -CRS as truncated version of cyclin B1 can be considered as an authentic substrate for mitotic kinases, we have performed kinase assays with Cdc2 and MAPK. We generated GST-tagged CRS mutants, each of them carried one mutation resulting in an exchange of serine to alanine (Figure 5a ). In agreement with previous observations (Borgne et al., 1999; Hagting et al., 1999) we could demonstrate that only mutations of Ser-126 and Ser-128 reduced the phosphorylation of GST -CRS by MPF significantly. Thus, MPF can phosphorylate the first two serine residues within the CRS (Figure 5b , lanes 2 and 3). The low signal intensity is most likely due to the catalytic preference of Cdc2 towards its heterodimeric partner compared to exogenously added cyclin B1.
Furthermore, cyclin B1 in Xenopus eggs has been reported to be phosphorylated at Ser-94 or Ser-96 by MAPK (Erk2) (Izumi and Maller, 1991) . To test the ability of MAPK (Erk2) to phosphorylate human cyclin B1, we subjected different CRS mutants to kinase assays. Replacing Ser-126 or Ser-128 by alanine in human cyclin B1 corresponding to Ser-94 and Ser-96 in Xenopus resulted in reduced signal intensity but did not abolish phosphorylation completely suggesting that MAPK (Erk2) has the potential to phosphorylate both serines (Ser-126, Ser-128) within the CRS (Figure 5c , lanes 2 and 3). In contrast, CK II could not phosphorylate the CRS (data not shown).
Simultaneously with Cdc2 dephosphorylation cyclin B1 becomes phosphorylated at multiple sites predominantly within the CRS (Hagting et al., 1999) . Since the kinases responsible for this process have not been completely identified so far, Plk1 was tested as candidate kinase. CRS (wild-type) and three mutant forms S126A, S128A and S147A served as substrates for human Plk1. In contrast, Plk1 from Sf 9 cells failed to phosphorylate CRS-S133A (Figure 5d, lane 5) . Moreover, mutation of Ser-128 resulted in an attenuated phosphorylation of the CRS compared to CRSwild-type signals (Figure 5d, lane 4) . Furthermore, Figure 5E shows that Plk1 from Sf 9 cells phosphorylated a synthetic peptide corresponding to amino acids 129 -140 (133S-peptide) but not a peptide corresponding to amino acids 141 -154 (147S-peptide). Synthetic phosphorylated peptides (133pS, 147pS) served as negative control. Taken together, the CRS of human cyclin B1 is a multiple phosphorylation site for MAPK (Erk2) and Cdc2 at Ser-126 and -128, whereas Plk1 activity is directed towards Ser-133 in cyclin B1.
Cooperative activity of MAPK (Erk2) and Plk1 regulates the phosphorylation of cyclin B1 within its CRS Considering that the CRS of cyclin B1 is a multiple phosphorylation site for different mitotic kinases, we wondered whether phosphorylation occurs in a specific sequence of events. As shown above Plk1 and MAPK (Erk2) have both the ability to phosphorylate the CRS of cyclin B1. When the CRS was prephosphorylated by MAPK (Erk2) under non-radioactive conditions, subsequent radioactive labeling of the CRS by Plk1 towards wild-type CRS was enhanced 3 -4 fold ( Figure  6a ). To assess that MAPK (Erk2) was completely removed prior to the kinase assay with Plk1, we added 32 P-ATP to the pretreated CRS. In this case radioactive labeling of the substrate was not observed (data not shown). In addition, prior to Plk1 phosphorylation the CRS was preincubated with MPF. A synergistic effect was also observed but less prominent as that of pretreating with MAPK (Erk2). This might be due to the weak phosphorylation of the CRS by MPF.
Then, we examined various mutants of CRS (S126A, S128A, S133A and S147A) to determine whether their prephosphorylation by MAPK (Erk2) or MPF influences subsequent phosphorylation by Plk1. The most intriguing result of those experiments was that after pretreatment with MAPK (Erk2) CRS-S133A turned out to be phosphorylatable by Plk1 (Figure 6b ) which was impossible before (Figure 5d , lane 5). We could exclude that the phosphorylation of CRS-S133A in Plk1-based kinase assays was due to remaining MAPK (Erk2). To confirm that the phosphorylation of S126 and S128 in cyclin B1 by Erk2 was responsible for the new additional phosphorylation site in CRS-S133A for Plk1, we tested a triple mutant CRS-S126,128,133A in Figure 6c it was not phosphorylated by Plk1 regardless of Erk2-pretreatment. In contrast, CRS-S126,128,147 was still nicely phosphorylated by Plk1 (Figure 6d , lane 2). The pretreatment of Erk2 did not enhance the phosphorylation signal by Plk1 (Figure 6d, lane 3) . Moreover, pretreatment of CRS-S147A with MAPK (Erk2) did not abolish the Plk1 mediated phosphorylation (data not shown). In summary, these data indicate that the phosphorylation of Ser-126,128 in cyclin B1 generates a new phosphorylation site for Plk1.
Plk1 exhibits strong binding affinity to full-length cyclin B1 compared to its CRS alone
To investigate whether the CRS can bind considerable amounts of Plk1, we performed further pull-down assays using different mutated GST -CRS constructs. As shown in Figure 7a large amounts of GST -CRS constructs were required to bind detectable amounts of 35 S-labeled Plk1. In contrast, much less His-tagged fulllength cyclin B1 was able to bind more than 30% of A total of 0.5 mg of peptide 133S, phosphorylated 133pS, 147S or phosphorylated 147pS were used for kinase assays with Plk1. The reaction mixtures were separated using peptide SDS gels and followed by autoradiography Mutation of 133 serine to alanine in full-length cyclin B1 reduced its phosphorylation signal by Plk1 in vitro and in vivo Subsequently, we mutated serine 133 to alanine in fulllength cyclin B1. Transfected cyclin B1, immunoprecipitated from 293 cells with GFP antibodies, served as a substrate for kinase assays with Plk1. Cyclin B1-S133A exhibited reduced phosphorylation signal by Plk1 compared to wild-type cyclin B1 (Figure 8 ). As a first step towards exploring the complexity of cyclin B1 phosphorylation in its CRS-region in vivo, HeLa cells transfected with CFP-cyclin B1 (wild-type) or CFP-cyclin B1-S133A were labeled with 32 P, then immunoprecipitated and subjected to electrophoretic separation ( Figure 9 ). As shown by autoradiography wild-type cyclin B1 incorporated more 32 P than cyclin B1-S133A. In a series of experiments the labeling of cyclin B1-S133A was found to be reduced by 25% compared to the wild-type protein in vivo suggesting that Ser-133 is a phoshorylation site in cyclin B1 in living cells.
Phosphorylation of Ser-133 within the CRS is required for accelerated nuclear import of cyclin B1
Since phosphorylation within the CRS of human cyclin B1 enhances its nuclear import as well as retarding its export, we evaluated the role of Ser-133. For this purpose we compared the nuclear import rate of fulllength cyclin B1 carrying different CRS-mutations, which prevent phosphorylation by MAPK, Cdc2 and Plk1. The drug leptomycin B was added to transfected cells to inhibit nuclear export of cyclin B1. This method allowed us to study exclusively the import rate of different mutated cyclin B1 variants. As shown in Figure 10 changing serine to alanine at positions 126 and 128 decreased slightly the import rate compared to wild-type cyclin B1. An additional mutation at Ser-133 (a) Bacterially expressed GST and GST -CRS constructs were coupled to glutathione-sepharose beads (Pharmacia) and incubated with 35 S-labeled Plk1 followed by SDS -PAGE and autoradiography. Twenty-five per cent of the reaction mixture was loaded seperately to stain input with coomassie. (b) His-cyclin B1 and its mutants were coupled to Ni-NTA agarose beads (Qiagen). Pull down was performed as in a. After autoradiography the gel was rehydrated and stained with coomassie to visualize 100% of loaded input Figure 8 In vitro: Mutation of Ser-133 in full-length cyclin B1 reduced its phosphorylation by Plk1. The pECFP vector, pECFPcyclin B1 or pECFP-cyclin B1 S133A were transfected into 293 cells. With GFP antibody the cyclin B1 and its S133A mutant were immunoprecipitated from the cell lysates and served as substrates for kinase assay in vitro by Plk1. preventing phosphorylation by Plk1 shifted the balance of cyclin B1 towards a more cytoplasmic localization. Interestingly, mutation of Ser-133 alone retarded the translocation of cyclin B1 into the nucleus after a 2.5 h-treatment with leptomycin B but did not block the translocation completely.
Discussion
Plks represent serine/threonine kinases, which are highly conserved from yeasts to humans (Glover et al., 1998) . While a central role for Plks in regulating several stages of mitotic progression has been born out in several species, a key function of Plk1 seems to be the control of the mitotic entry: (i) The periodic accumulation of Cdc5 mRNA during the cell cycle in Saccharomyces cerevisiae suggested a role of Cdc5 at the G 2 /M boundary (Kitada et al., 1993) ; (ii) Mammalian cells exhibit also maximum Plk1 mRNA abundance and enzyme activity during G 2 /M phase, whereas low levels in G 1 phase and reaccumulation starting in S phase were found (Lake and Jelinek, 1993) ; (iii) Microinjection of Plk1 antibodies caused mitotic abnormalities in HeLa cells, whereas the same treatment of non-immortalized Hs 68 cells led to G 2 arrest (Lane and Nigg, 1996) ; (iv) The inhibition of Plk1 function by adenovirus delivery of a dominant-negative gene induced G 2 /M cell cycle arrest within 24 h in certain sensitive tumor lines (Cogswell et al., 2000) .
MPF is another key regulator of the G 2 /M transition. It is well established that phosphorylation of cyclin B1 is required for its biological activity as demonstrated by the fact that mutation of five critical serine phosphorylation sites to alanine inactivates cyclin B1, whereas mutation of the same residues to glutamic acid mimics phosphoserine which elevates the activity of cyclin B1 (Li et al., 1995) . Since the spatial and temporal distribution of cyclin B1 resembles mitotic properties of Plk1, we wished to examine whether both proteins are functional interactive. Data presented here provide evidence that cyclin B1 and Plk1 interact in vitro and in vivo. Still, we like to point out that the interaction of both proteins in vivo is Figure 9 Mutation of Ser-133 in full-length cyclin B1 reduced phosphorylation of cyclin B1 in vivo. HeLa cells were transfected with CFP-cyclin B1 wild-type or CPF-cyclin B1 S133A. Subsequently cells were labeled for 3 h with 32 P in vivo. Labeled CFP-cyclin B1 was immunoprecipitated followed by SDS -PAGE and autoradiography (a). Input control (b). The radioactivity was quantified using a gel documentation system (Kodak) and normalized to the input control (c). Results represent means+s.d. of three independent experiments Figure 10 Mutation of Ser-133 in cyclin B1 inhibited its import to the nucleus. (a) Indirect immunofluorescence of translocated cyclin B1 and its mutants. HeLa S3 cells were transiently transfected with wild-type cyclin B1 and its mutants as indicated. Sixteen hours after transfection cells were treated with 3 ng/ml leptomycin B for 2.5 h to inhibit CRM1-mediated export. Transfected cyclin B1 was detected with Anti-Xpress antibody (Invitrogen) followed by DTAF-conjugated anti-mouse antibody. Nuclei were stained with bisbenzimide (H 33342). (b) Schematic representation of a. Approximately 100 cells per cyclin B1 mutant were examined and percentages of each category are shown. Experiments were repeated three times rather weak as expected for an enzyme/substrate reaction. Plk1 phosphorylates full-length cyclin B1. Furthermore, kinase assays using CRS mutants revealed that Plk1 phosphorylates Ser-133 within the CRS of human cyclin B1. The mutation of Ser-133 in intact cyclin B1 reduced the phosphorylation signal by Plk1. Cdc2 and MAPK (Erk2) have both the ability to phosphorylate Ser-126 and Ser-128 within the CRS. The immunofluorescence study revealed that a mutation of Ser-133 reduced the nuclear import rate of a Xpress-tagged version of cyclin B1. Still, multiple serine mutations are necessary to block the nuclear import completely suggesting that the combined activity of multiple kinases is required for the rapid import of cyclin B1 into the nucleus.
In parallel to our investigations, it was demonstrated that Plx from Xenopus and Plk1 from mammalian cells have the potential to phosphorylate Ser-147 in cyclin B1 (Toyoshima-Morimoto et al., 2001) . This observation differs from our results which provide evidence for Ser-133 as phosphorylation site for Plk1 in cyclin B1:
(1) CRS-S133A, a single mutation within the CRS totally abolished the phosphorylation by Plk1 ( Figure  5d ); (2) CRS-S126,128,147A was still strongly phosphorylated by Plk1 whereas CRS-S126,128,133A did not serve as a substrate for Plk1 ( Figure 6c,d) ; (3) Only the peptide containing Ser-133 was phosphoryated by Plk1 ( Figure 5e ); (4) The phosphorylation signal was reduced over 50% when Ser-133 was replaced by alanine in full-length cyclin B1 ( Figure 8) ; (5) After pretreatment with MAPK (Erk2) the CRS-S147A is still phosphorylated by Plk1, indicating that Ser-147 is not the major phosphorylation site for Plk1 (data not shown); and (6) In the study by Toyoshima-Morimoto et al. (2001) cyclin B1-S126,128,133A showed only about 50% phosphorylation by His-Plk1 as well as by Flag-Plk1 compared to 100% phosphorylation of cyclin B1-S126,128A. Taken together, our observations propose that Ser-133 is the major phosphorylation site for Plk1 in our system.
The discrepancy between these two works resulted possibly from (1) different mutant forms of cyclin B1 utilized: Nishida and colleagues (Toyoshima-Morimoto et al., 2001) used mostly double mutants (Ser-126,128A) of cyclin B1 to test the substrate specificity of Plk1; (2) We used Plk1 purified from Sf 9 cells whereas Nishida's team used Plk1 from bacteria. Plk1 from different expression systems could possess different post-modifications or folding which are important for kinase activity and specificity. The first hypothesis raised the question whether the exchange of serine to alanine at positions 126 and 128 in cyclin B1 might have influenced the substrate recognition by Plk1 due to threedimensional alterations. We tried to shed new light on this issue by using MAPK (Erk2) and/or MPF which are physiological kinases for Ser-126 and Ser-128 within cyclin B1: (1) Pretreatment with MAPK (Erk2) or MPF resulted in an enhanced phosphorylation of wild-type CRS by Plk1; (2) The exchange of serine to alanine at position 128 attenuated the phosphorylation of the CRS by Plk1; (3) The pretreatment by MAPK (Erk2) even generated an additional phosphorylation site for Plk1 in CRS-S133A, but not in CRS-S126,128,133A indicating the phosphorylation of Ser-126 and Ser-128 by Erk2 contributes to the generation of new Plk1 sites. So the exchange of Ser-126 and Ser-128 to alanine which Toyoshima-Morimoto et al. (2001) used might change the recognition site in cyclin B1. In our system Ser-133 seems to be the major target of Plk1 depending on the synergistic activity of MPF and MAPK (Erk2) which act in concert to promote a rapid entry of MPF into the nucleus.
Wild-type human cyclin B1 is predominantly cytoplasmic throughout G 2 phase until it very rapidly translocates into the nucleus about 10 minutes before nuclear envelop breakdown (Hagting et al., 1999) . The cyclin B1 phosphorylation mutant in which all serine residues were altered to alanine residues, translocates significantly later than the wild-type protein. Hagting et al. (1999) suggested that the 5xA mutant of cyclin B1 could only enter the nucleus when the nuclear envelop began to break down. Various studies revealed that multiple phosphorylations within the CRS of human and Xenopus cyclin B1 are required for its translocation to the nucleus at prophase (Hagting et al., 1998; Yang et al., 2000) . Rendering any of the four CRS serine residues unphosphorylatable decreased also cyclin B1 import rates to wild-type levels in Xenopus (Yang et al., 2000) . In our study, we suggest that a single mutation of Ser-133 in cyclin B1 reduced its import rate in mammalian cells clearly. The inhibition of triple mutants (S126, 128, 133A) was even more pronounced. Thus, it seems that each phosphorylation site within the CRS contributes to the nuclear import of cyclin B1.
Different investigators have also shown that MAPKs act in concert to integrate signals from different pathways. Blenis and colleagues (Chen et al., 1993) revealed that two growth-regulated kinases, 90-kDa ribosomal S6 kinase (RSK) and MAPK (Erk1) cooperatively phosphorylate the transrepression domain of c-Fos. Our data support the idea that phosphorylation by MAPK enhances subsequent phosphorylation of the CRS by Plk1. Thus, as a novel example for the cooperative activity of serine/threonine kinases we demonstrated the concerted action of MAPK, MPF and Plk1 for the phosphorylation of the CRS. In addition to cooperation, a synergistic regulation by multiple kinases (JNK, MAPK, p38 and CKII) was described for the control of the cellular localization of the transcription factor NFATc (Porter et al., 2000) . The phosphorylation of Ser-172 by MAPK/SAPK family members could act to prime the following CKI-mediated phosphorylation of neighboring serines in a processive fashion. Here, our data imply beyond a cooperative kinase activity also a synergistic mode of action, because it was apparent that phosphorylation of Ser-126 and Ser-128 by MAPK (Erk2) enhanced phosphorylation by Plk1. This mechanism could also be due to the generation of an improved phosphorylation site for Plk1. Since the nuclear import rate of cyclin B1 at the G 2 /M transition is determined by the phosphorylation status of the CRS, priming by MAPK (Erk2) and/or Cdc2 could increase the affinity for additional phosphorylation events considerably. This kinetics of CRS phosphorylation could explain the rapid shift of cyclin B1 at G 2 / M to a predominantly nuclear localization. Further experiments in vivo and in living cells will shed more light on the synergistic action of MPF, MAPK and Plk1.
Materials and methods
Cell culture, synchronization, transfection and preparation of extracts HeLa S3 cells were grown in Ham's F-12 medium supplemented with 10% fetal bovine serum and 2 mM Lglutamine at 378C/5% CO 2 . HeLa S3 cells were synchronized to the G 1 /S boundary by double-thymidine block. Briefly, exponentially growing cells were treated with 2 mM thymidine for 14 -16 h and released by washing with fresh medium. Cells were grown for 8 h and then treated again with thymidine for further 14 -16 h. To obtain G 2 /M arrest, after initial thymidine treatment and 8 h release cells were exposed to 50 ng/ml nocodazol for 14 h. COS-7 cells were grown in DMEM with 10% fetal bovine serum and 2 mM L-glutamine. Transfection was performed using Lipofectamine Plus according to the manufacturer's instructions (Gibco -BRL). Cell extracts were prepared as described (Hock et al., 1998b) .
Antibodies, Western blots and immunoprecipitation
Monoclonal Plk1 antibodies used for immunoprecipitations were purchased from Zymed. Polyclonal Plk1-, cyclin B1-and Cdc2-antibodies were from Santa Cruz. Western blot analysis and immunoprecipitations were performed as described (Hock et al., 1998b) . extracts, immunoprecipitation of cyclin B1 and PAGE were done as described above.
